Stockreport

ESMO 2024: TROP2-directed ADCs show promise in recurrent gynecological cancers [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF ovarian cancers (OC). However, both cancers are frequently marked by recurrence and the eventual development of resistance to platinum-based (Pt-based) regimens, undersc [Read more]